TSYS将以16.5亿美元收购德国IOM Isotope，以扩大放射性辐射足迹

2026-09-21 12:52

Australian biotechnology company Telix Pharmaceuticals (TLX) has agreed to acquire Germany's ITM Isotope in a $1.65B deal, the companies said on Monday, with the deal expected to strengthen Telix’s position as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture, and deliver innovative treatments to patients globally.
Under the terms of the agreement and subject to shareholder approval, Telix will acquire 100% of ITM for $1.65B upfront on a cash-free, debt-free basis, comprising $1.25B in Telix stock, $302M in assumed net debt, and $96M in management rollover equity and transaction costs.
The combined organization is expected to generate unaudited pro forma 2026 revenue and income exceeding $1.3B, based on management estimates. ITM’s radioisotope manufacturing business is profitable and generates cash flow.
Continued growth from manufacturing, cost savings and further targeted synergies and pipeline optimization are expected to support a positive EBITDA contribution in 2027 and onward.
Munich-based ITM Isotope is a global player in radioisotope production and radiopharmaceutical development, Telix said. Telix managing director Christian Behrenbruch said the two companies had worked closely together for many years.

More on Telix Pharmaceuticals